This study was designed to investigate the effects of smoking on endothelial function in 88 healthy blood donors: 48 smokers and 40 non-smokers. Two markers of endothelial dysfunction, plasminogen activator inhibitor-1 (PAI-1) and nitric oxide (NO) levels, were measured at baseline and after phlebotomy. It has been proposed that phlebotomy acutely activates the renin-angiotensinaldosterone system, thereby activating endothelial activity and increasing PAI-1 and NO expression. At baseline there were no significant differences between smokers and non-smokers in terms of PAI-1 expression and NO levels. After phlebotomy, both PAI-1 and NO levels were significantly increased in both groups. The increase in PAI-1 was more pronounced in smokers and the increase in NO was more pronounced in nonsmokers. These findings suggest that smoking causes endothelial dysfunction, even in healthy smokers, which may remain silent until a clinically evident disorder develops.
Introduction
In the past decade, endothelial dysfunction has arisen as a popular issue because of its probable contribution to the development of several diseases. Relatively recently, studies have shown that the endothelium not only forms an inert barrier within the blood vessel but it also plays a central role in many physiological events within the circulatory system. The endothelium, for example, secretes many physiologically active substances, forms a thromboresistant layer within the vessel, prevents thrombosis, modulates vessel tone, growth, homeostasis, inflammation and many other functions throughout the circulatory system. Thus, endothelial dysfunction is seen in several conditions, such as atherosclerosis, hypercholesterolaemia, diabetes, hypertension, heart failure and ageing, as well as in cigarette smokers. 1 -4 Smoking is a major worldwide health problem, it influences a large number of diseases and is a major cause of many conditions; in several studies, smoking has been shown to be associated with endothelial H Buyukhatipoglu, O Tiryaki, C Usalan Impaired endothelial responses in healthy cigarette smokers dysfunction and coagulation-fibrinolytic system abnormalities. 4, 5 Plasminogen activator inhibitor-1 (PAI-1) and nitric oxide (NO) are both endothelial-derived substances: PAI-1 is the major physiological inhibitor of fibrinolysis, and increased levels of PAI-1 are associated with recurrent thrombotic attacks and atherosclerosis. 6, 7 Although there is evidence that smoking is associated with hypertension and thromboembolic events, the relationship between endothelial function, fibrinolysis and smoking is not well understood in normotensive subjects. 8 -10 We suggest that, even in normotensive patients, smoking causes endothelial dysfunction but, under basal conditions it does not become apparent. We also suggest that silent endothelial dysfunction begins before any smoking-related disease becomes clinically evident.
To test this hypothesis, this study was designed to activate the renin-angiotensinaldosterone system (RAAS) via phlebotomy in healthy cigarette smoking and nonsmoking blood donors and to measure the effect on plasma levels of PAI-1 (an index of impaired fibrinolysis) and NO (an index of endothelial function). This method of activating the RAAS and, thereby, inducing an endothelial response was different to those used in previous studies in which RAAS was activated by a low-salt diet or diuretic agents. 11, 12 Phlebotomy has been shown previously to result in an acute, dependable and dramatic activation of the RAAS. 13
Subjects and methods

SUBJECTS AND SUBJECT SCREENING
This prospective, observational study included normotensive healthy blood donors from among voluntary blood donors who attended Gaziantep University Blood Centre.
This study was approved by the local ethics committee of Gaziantep University School of Medicine and all subjects provided written informed consent to participate.
The inclusion criteria were as follows: (i) no current disease or significant health condition including obesity; (ii) not currently using any medications; (iii) no consumption of alcohol over the past 2 weeks and no history of chronic alcohol use; and (iv) no history or evidence of drug abuse. All subjects recruited for this study underwent a detailed medical history and physical examination. A 20-ml blood sample was drawn under a fasting state for routine laboratory biochemical analysis. All subjects also underwent urinalysis. Blood pressure was measured on both arms using a mercury sphygmomanometer and cuffs were adapted to arm circumference after 15 min in a recumbent position. Blood pressure was measured at two time points and in both arms while subjects were in the sitting position. A posterior-anterior chest X-ray was performed on each subject. Any subject who failed to meet the inclusion criteria, including those subjects who were found to have any abnormalities in any of the baseline evaluations, were excluded from the study. Any smoker included in the study had to have been a smoker for at least 5 years and have a mean cigarette consumption of 20 pack-years.
STUDY PROTOCOL
Eligible subjects were divided into two agematched groups according to smoking status: smokers and non-smokers. To measure plasma renin activity (PRA), plasma PAI-1 activity and plasma NO levels, blood samples were collected from a large antecubital vein at 09:00 h on the study day and prior to phlebotomy (basal conditions) after 30 min rest in the sitting position. All H Buyukhatipoglu, O Tiryaki, C Usalan Impaired endothelial responses in healthy cigarette smokers venipunctures were carried out without interruption of venous flow using a 19-gauge butterfly needle connected to a plastic syringe. After 1 h, while subjects were still in a sitting position, 400 -500 ml of venous blood was taken by phlebotomy. The volume of blood taken was based on body surface area (m 2 ), so that the same volume was drawn per m 2 (250 ml × body surface area). After phlebotomy, an additional 15 ml of venous blood was drawn for PRA, PAI-1 and NO measurements. Blood taken before and after phlebotomy was immediately transferred to polypropylene tubes containing 1 ml trisodium citrate (0.109 mol/l). The tubes were centrifuged immediately at 3000 g at 18°C for 15 min. The plasma was stored at -70°C until analysis. All samples were measured at room temperature. All subjects also underwent routine biochemical and haematological monitoring before and after phlebotomy. Blood taken before phlebotomy was assumed to reflect the RAAS activation (PRA) level and endothelial function (PAI-1 activity and NO level) under basal conditions (baseline). Blood taken after phlebotomy was regarded as reflecting stimulated RAAS and endothelial functions.
BIOCHEMICAL ASSAYS
The PRA level was estimated using a radioimmunoassay kit (CisBio International, Gif-sur-Yvette, France). The reference range for a supine adult with salt intake was 0.2 -5.7 ng/ml per h. Levels of PAI-1 were measured using a chromogenic assay (Biopool, Umeå, Sweden). The intra-and inter-assay coefficients of variation were 5.2 -8.7% for PRA and 6.5 -9.4% for PAI-1. Plasma NO metabolite levels were measured by using a colorimetric assay based on the Griess reaction. NO, nitrite (NO 2 ) and nitrate (NO 3 ) levels were deproteinized by using 100 µl ZnSO 4 and 100 µl NaOH. A 14 µM Griess solution and a 1 mM sodium phosphate solution were prepared: equal amounts of 0.2 mM N-nitrosodiethylamine and 0.5 mM sulphonamide were mixed to prepare the Griess solution. Using 100 µl plasma, 200 µl 10 mM nicotinamide adenine dinucleotide phosphate (NADPH), 200 µl 50 µM glucose-6-phosphate (G6P), 100 µl 400 U/l G6P dehydrogenase and 200 µl 200 U/l nitrate reductase enzyme were added to convert NO 3 to NO. Griess solution (200 µl) was then added and absorbance was measured at 550 nm using a microplate spectrophotometer (SpectraMax 250; Molecular Devices, Sunnyvale, CA, USA). The results were calibrated using serial dilutions of a 10 mM stock nitrate solution and were measured as µmol/l. Each samples was analysed twice and the mean value calculated. Reactions exhibited linearity between 0.25 and 100 µmol/l. The within-and between-day variation coefficients for this method were > 4% and > 7%, respectively.
STATISTICAL ANALYSIS
Intra-group differences from baseline were evaluated by means of paired t-tests. Differences between the two groups (smokers and non-smokers) were assessed by means of independent sample t-tests. Data were presented as mean ± SD. All data were analysed using SPSS ® version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value of < 0.05 was considered to be statistically significant.
Results
The study included 88 normotensive healthy blood donors: 48 smokers and 40 nonsmokers. The smoking group consisted of 36 males and 12 females with a mean ± SD age of 42 ± 24 years. The non-smokers consisted of 26 males and 14 females with a mean ± H Buyukhatipoglu, O Tiryaki, C Usalan Impaired endothelial responses in healthy cigarette smokers SD age of 43 ± 26 years. Under baseline conditions, the PRA, PAI-1 and NO levels did not differ significantly between the two groups ( Table 1) . Levels of PRA, PAI-1 and NO increased significantly after phlebotomy in both groups (P < 0.05; Table 1 ). Although the size of the increase in PRA levels did not differ significantly between smokers and non-smokers, the increase in plasma PAI-1 levels was significantly more pronounced and the increase in the NO levels was significantly less pronounced in subjects that smoked compared with those that did not smoke (P < 0.05; Table 1 ).
Discussion
Smoking has been shown to be associated with endothelial dysfunction in several studies. 14 Endothelial dysfunction is implicated in a large number of diseases and conditions, 1 -4 and nearly all hypertensive patients have endothelial dysfunction. 15, 16 Whether endothelial dysfunction leads to hypertension or hypertension induces further endothelial dysfunction is uncertain. 16 Nevertheless, smoking is a risk factor for hypertension and thromboembolic events and also causes endothelial dysfunction. 17 The present study focused on the effects of smoking on endothelial dysfunction by measuring the levels of the endothelial-derived factors NO and PAI-1, both of which have an important role to play in the pathogenesis of hypertension and thromboembolic events.
In a previous study of genetically susceptible normotensive patients who had not already developed hypertension but in whom at least one had hypertension, it was demonstrated that impaired endothelial dysfunction occurred under phlebotomyinduced RAAS-stimulated conditions but not under basal conditions in the absence of phlebotomy. 18 Endothelial dysfunction is an ongoing process: it can be caused by smoking, however the pathological effects of endothelial dysfunction may remain silent until they become clinically evident. 4, 5, 14 PAI-1 and NO are endothelial-derived factors and activation of the RAAS increases their levels. 14, 19, 20 In most clinical studies, low-salt diets or diuretic agents have been used to activate the RAAS, which induces significant increases in PRA, the level of which is the most important indicator of RAAS activation. 18, 21 A decrease in renal perfusion constitutes the underlying physiological stimulus. In some of these studies, basal levels of various RAAS components have been shown to be normal; however, significant abnormalities have also been shown in response to stimulated RAAS
Smokers
Non-smokers (n = 48) (n = 40) Values are mean ± SD. a P < 0.05 post-phlebotomy versus baseline; b P < 0.05 smokers versus non-smokers.
Parameters
TABLE 1: Levels of plasma renin activity (PRA), plasminogen activator inhibitor-1 (PAI-1) and nitric oxide (NO) under basal conditions (baseline) and after phlebotomy in healthy smoking and non-smoking blood donors
H Buyukhatipoglu, O Tiryaki, C Usalan Impaired endothelial responses in healthy cigarette smokers activation. 6, 19, 20 In the present study, RAAS was activated using phlebotomy, which is considered to be a more efficient method. From a pathophysiological point of view, it might be expected that the acute decrease in renal perfusion observed with phlebotomy would be a more accurate indicator of RAAS activation than with low-salt diets and diuretics. 13 Thus, RAAS was acutely stimulated by phlebotomy, which is an effective physiological means of RAAS activation, and plasma renin levels were significantly increased, indicating that RAAS stimulation occurred.
As expected, no significant difference was found between smokers and non-smokers under basal conditions in the present study. Both subject groups experienced increased expression of endothelial-derived PAI-1 and NO after phlebotomy. It is interesting, however, that the PAI-1 response was more pronounced in smokers than in non-smokers and that the NO response was more pronounced in non-smokers than in smokers. This suggests the existence of an underlying endothelial dysfunction in the normotensive healthy smoking subjects. Under basal conditions, the endothelium functions to maintain vessels in a relatively dilated state and this is mainly achieved by maintaining adequate NO secretion. 2, 22 The endothelial-dependent response is principally regulated by the release of NO. 23 Since, in the present study, the NO response was more pronounced in the non-smoking group than in the smoking group, it suggests that the endothelial function was more intact in non-smokers than in smokers. The other important finding, that the PAI-1 response was more pronounced among smokers than the non-smokers, suggests that fibrinolytic activity was more intact in the non-smokers compared with smokers. PAI-1 is one of the major regulators of the fibrinolytic system and dysregulated secretion of PAI-1 (manifested as increased secretion) is associated with an increased rate of thromboembolic events. 24, 25 This study showed, therefore, that a disruption in endothelial function exists in healthy normotensive smokers, but whether this dysfunction might cause a manifest cardiovascular disorder is unclear. It could be argued that the disruption of the physiological RAAS axis is an early change and that, in subsequent years, this disruption may cause hypertension and other related cardiovascular disorders. Longterm follow-up is necessary to investigate whether this is the case. One limitation of this study was that only two parameters of endothelial dysfunction were measured and there are many other relevant parameters that could be studied. Smoking is likely to disrupt other endothelial functions, which should also be investigated.
In conclusion, smoking is a major health problem and there is overwhelming evidence of its harmful effects. Endothelial dysfunction predisposes subjects to many disorders and has been implicated in their underlying pathophysiology. The findings of this study suggest that endothelial dysfunction exists before it becomes clinically manifest. Cessation of smoking may prevent the possible development of many diseases in which endothelial dysfunction is a contributory factor. Although it cannot definitively be said that smokers will develop endothelialdysfunction-related disorders, such as hypertension or thromboembolic events, it is evident from this study that smokers have a greater risk.
